Latest therapies in AML: IMGN632, magrolimab & gilteritinib

The armamentarium of therapeutic modalities in acute myeloid leukemia (AML) has taken several strides in the last few years as a result of a greater understanding of the genomic landscape disease as well as how resistance to conventional therapies can develop.

At the virtual 62nd American Society of Hematology 2020 Annual Meeting and Exposition (ASH 2020), we spoke with key opinion leaders in AML who shared the novel classes of drugs currently investigated in this disease area, which provide the field new opportunities for effective combination strategies.

In this podcast, Marina Konopleva, of the University of Texas MD Anderson Cancer Center, Houston, TX, David Sallman, of Moffitt Cancer Center, Tampa, FL, and Naval Daver, of the University of Texas MD Anderson Cancer Center, discuss some of the latest updates in AML presented at this year’s virtual American Society of Hematology (ASH) meeting.

The post Latest therapies in AML: IMGN632, magrolimab & gilteritinib appeared first on VJHemOnc.